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Abstract Although the primary role of chemokines and their receptors is controlling the trafficking of leukocytes
during inflammatory responses, they also play pleoitropic roles in cancer development. There is emerging evidence that
cancer cells produce chemokines that induce tumor cell proliferation or chemotaxis in various cancer types. We have
previously reported that MCP-1 acts as a paracrine and autocrine factor for prostate cancer (PCa) growth and invasion. As
the cellular effects of MCP-1 are mediated by CC chemokine receptor 2 (CCR2), we hypothesized that CCR2 may
contribute PCa progression. Accordingly, we first determined CCR2 mRNA and protein expression in various cancer cell
lines, including PCa and other cancer types. All cells expressed CCR2 mRNA and protein, but in PCa, more aggressive
cancer cells such as C4-2B, DU145, and PC3 expressed a higher amount of CCR2 compared with the less aggressive
cancer cells such as LNCaP or non-neoplastic PrEC and RWPE-1 cells. Further, we found a positive correlation between
CCR2 expression and PCa progression by analyzing an ONCOMINE gene array database. We confirmed that CCR2
mRNAwas highly expressed in PCametastatic tissues comparedwith the localized PCa or benign prostate tissues by real-
time RT-PCR. Finally, CCR2 protein expression was examined by immunohistochemical staining on tissue microarray
specimens from 96 PCa patients and 31 benign tissue controls. We found that CCR2 expression correlated with Gleason
score andclinical pathologic stages,whereas lower levels ofCCR2were expressed innormal prostate tissues. These results
suggest that CCR2 may contribute to PCa development. J. Cell. Biochem. 101: 676–685, 2007.  2007 Wiley-Liss, Inc.
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Bone is the most frequent site for distant
metastasis from prostate cancer (PCa). It was
reported that skeletal metastases occurred in
up to 90% of patients dying from PCa [Abrams
et al., 1950;Ranaet al., 1993;Landis et al., 1999;
Bubendorf et al., 2000]. Skeletal metastases
cause significant complications including
severe bone pain, impaired mobility, pathologi-
cal fracture, spinal cord compression, and
hypercalcemia [Coleman, 1997; Moul and Lipo,
1999]. Despite advances inmanagement of PCa,
skeletal metastases remain incurable. Strate-
gies to inhibit PCametastasis include targeting
the dynamic and bidirectional interactions
between tumor cells and the bone microenvir-
onments. The bone microenvironment is com-
posed of the extracellular matrix, stromal cells,
osteoblasts, osteoclasts, and endothelial cells
that may produce unique soluble factors,
including growth factors and chemotactic fac-
tors, to promote PCa progression in bone.
Chemokines are classified into four major
families based upon the relative position of
cysteine residues near the NH2-terminus:
CC, CXC, C, and CX3C [Rossi and Zlotnik,
2000]. Chemokines activate receptors, members
of large families of seven-transmembrane
G-coupled proteins, and play critical roles in cell
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migration during inflammatory responses.
In addition, they significantly impact normal
development, atherosclerosis, and angiogenesis.
Increasing knowledge of the effects of chemo-
kines on different aspects of tumor cell biology,
including modulation of proliferation, angiogen-
esis, and immune response to tumor, has begun
to emerge [Strieter, 2001].
Monocyte chemotactic protein-1 (MCP-1) is a
member of the CC chemokine superfamily
that plays a critical role in recruitment and
activation ofmonocytes during acute inflamma-
tion and angiogenesis [Galasso et al., 2000;
Bernardini G et al., 2003; Charo and Taubman,
2004]. A variety of cancer cells that home to
bone, including PCa, breast cancer and my-
eloma cells, express MCP-1 and its receptor
CCR2 [Valkovic et al., 1998; Vande Broek et al.,
2003; Lu et al., 2006; Mestdagt et al., 2006]. In
patients with breast cancer and ovarian cancer,
MCP-1 levels are increased in their serum,
which correlating with stage of tumors develop-
ment [Hefler et al., 1999; Lebrecht et al., 2001].
In squamous cell carcinoma of the esophagus,
MCP-1 expression in cancer cells is correlated
with venous invasion, distant metastasis, and
lymph node metastasis [Koide et al., 2004].
Further, our data indicate that MCP-1 is
chemotactic for PCa cells [Lu et al., 2006]. In
addition,MCP-1 appears to induce proliferation
of PCa cells [Lu et al., 2006], osteoclast fusion
and osteoclast formation in vitro [Kim et al.,
2006]. MCP-1 is also produced by osteoclasts
and is upregulated by RANKL and TNF-a in
osteoclasts [Graves et al., 1999; Arendt et al.,
2002; Park et al., 2005]. Thus, MCP-1, through
its receptor CCR2, may play a critical role in
tumor development in bone microenvironment.
Chemokine receptors are expressed by a
variety of tumor cell types [Dwinell et al.,
1999; Scotton et al., 2001; Soejima and Rollins,
2001]. Specifically, CCR2 is expressed in var-
ious cancer types including PCa and breast
cancers. Certain types of breast cancer and PCa
cell lines also respond toMCP-1 in vitro [Youngs
et al., 1997; Lu et al., 2006] indicating presence
of functional CCR2 receptors. However, CCR2
expression in different cancer cells and the
correlation between CCR2 expression and
PCa progression have not been defined. In
this study, we first determined CCR2 mRNA
expression in various cancer cell lines including
PCa, lung cancer, breast cancer, and myeloma.
Further, CCR2 mRNA expression in specimens
from PCa patients with bone metastases were
examined by analyzing an ONCOMINE gene
array database and validated by real-time RT-
PCR and compared to localized PCa or benign
tissues. Finally, CCR2 protein expression was
determined by immunohistochemical staining
on tissue microarray specimens from 96 PCa
patients and 31 benign controls. The correlation
between CCR2 expression with Gleason score
and clinical pathologic stages was analyzed.
MATERIALS AND METHODS
Antibodies and Reagents
Goat anti-human CCR2 polyclonal antibody
and isotype control antibody (normal goat IgG)
were purchased from Calbiochem (San Diego,
CA). The CCR2 antibody is human specific and
does not cross react with other chemokine
receptors according to the manufacture proto-
col. The anti-human PSA polyclonal antibody
was purchased from Ventana Medical Systems
(Tucson, AZ). All chemical reagents were
purchased from Sigma (St. Louis, MO).
Cell Culture
PCa LNCaP, PC3 and DU145 cells, RWPE-1
(non-tumorigenic human prostate epithelial
cells), hFOB (SV 40 large T antigen transfected
and immortalized human osteoblasts), and
HBME (human bone morrow endothelial cells)
were obtained from the American Type Culture
Collection (ATCC, Rockville, MD). C4-2B cells
derived from its parental LNCaP but with
characteristics of skeletal metastasis were
obtained from UroCor (Oklahoma City, OK).
A549, H1299 (human non-small-cell lung carci-
noma cell lines), and BEAS2B (non-neoplastic
bronchi epithelial cells) were kindly provided
by Dr. Xue Wang, at the University of Pitts-
burgh, Pittsburgh, PA. MDA-MB-231 and
MCF-7 (breast cancer cells) were kindly pro-
vided by Dr. Shiyuan Cheng, at the University
of Pittsburgh. KAS (interleukin-6-responsive
myeloma KAS-6/1 cells) were kindly provided
by Dr. G. David Roodman, at the University of
Pittsburgh. Prostate epithelial cells (PrEC)
were purchased from Cambrex (Walkersville,
MD). LNCaP, PC3, DU145, H1299, and KAS
cells were cultured in RPMI 1640 media
(Invitrogen, Carlsbad, CA). The KAS cells were
grown in RPMI media supplemented with
recombinant human IL-6 (10 ng/ml). Human
FOB cells were grown in media with 50%
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DMEM and 50% Ham’s F12 media (Invitrogen)
at 348C. At this temperature, the cells exhibit
rapid cell division due to the establishment of
this cell line by transfection of a temperature
sensitive expression vector pUCSVtsA58. C4-
2B cells were maintained in T media [80%
DMEM, 20% Ham’s F12 medium (Invitrogen),
5 mg/ml insulin, 13.6 pg/ml triiodothyronine,
5 mg/ml transferrin, 0.25 mg/ml biotin, and 25 mg/
ml adenine]. HBME, A549, BEAS2B, and
MDA-MB231 cells were cultured in DMEM
media. MCF-7 cells were cultured in DMEM
media supplemented with 5 mg/ml insulin. All
cell cultures were supplemented with 1% peni-
cillin/streptomycin (Invitrogen) and 10% FBS
(HyClone, Pittsburgh, PA). PrEC were main-
tained in PrEGM BulletKit media (Cambrex).
The RWPE-1 cells were grown in Keratinocyte-
Serum Free medium supplemented with 5 ng/
ml human recombinant EGF and 0.05 mg/ml
bovine pituitary extract (Invitrogen). All cells,
except hFOB, were maintained in 10 cm tissue
culture dishes in a 378C incubator equilibrated
with 5% CO2 in humidified air.
Reverse Transcription-PCR
Total RNA was extracted from LNCaP, C4-
2B, DU145, PC3, PrEC, RWPE-1, BEAS2B,
A549, H1299, MDA-MB-231, MCF-7, KAS,
HBME, and hFOB cells; from benign prostate
tissue (three cases), localized PCa (three cases),
PCa with bone-metastases (seven cases), PCa
with liver-metastases (two cases), and PCawith
lymph node-metastases (two cases) using TRI-
zol reagent (Life Technologies, Gaithersburg,
MD), then subjected to RT-PCR for detection of
CCR2 mRNA. Cases of clinically localized PCa
were identified from a radical prostatectomy
series at the University of Michigan and
cases with PCa metastases were obtained from
a Rapid Autopsy Program through the Michi-
gan Prostate Specialized Programs of Research
Excellence (SPORE) Tissue Core. PCR primers
for CCR2 consisted of sense 50-CTG TCC ACA
TCT CGT TCT CGG TTT A-30 and antisense 50-
CCC AAA GAC CCA CTC ATT TGC AGC-30
resulting in a PCR product of 324 bp [Hanna
et al., 2003]. PCR primers for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, as control)
consisted of sense 50-CCA TGG AGA AGG CTG
GGG-30 and antisense 50-CAA AGT TGT CAT
GGA TGA CC-30 resulting in a PCR product
of 194 bp [Park et al., 2002]. RT-PCR was
performed with 1 mg of total RNA using the
Access RT-PCR system (Promega Corp., Mad-
sion, WI) in a thermal cycler (GeneAmp PCR
System 2700, Applied Biosystems, CA) under
the following conditions: first strand cDNA was
synthesized at 488C for 45 min; then denatured
at 948C for 2min for the first cycle and at 30 s for
additional 35 cycles; annealing was performed
at 558C for 30 s and extension at 728C for 60 s.
Final extension was at 728C for 7 min. The PCR
products were subjected to electrophoreses on a
1.5% agarose gel and stained with ethidium
bromide.
Real-Time RT-PCR
Total RNA was extracted as the same as in
RT-PCR. Real-time RT-PCR was performed in
an iCycler iQ multicolor real-time PCR detec-
tion system (Bio-Rad, Hercules, CA) using
iScript one-step RT-PCR kit with SYBR Green
(Bio-Rad). Primers for CCR2were sense 50-GAC
CAG GAA AGA ATG TGA AAG TGA-30, and
antisense 50-GCTCTGCCAATTGACTTTCCT
T-30 [Johrer et al., 2004]. PCR primers for
GAPDH were sense 50-CCA TGG AGA AGG
CTG GGG-30, and antisense 50-CAA AGT TGT
CAT GGA TGA CC-30. Synthesis of cDNA was
performed at 508C for 10 min, then denatura-
tion at 958C for 5min, followed by 45 cycles with
denaturation at 958C for 30 s, annealing at 558C
for 15 s, and elongation at 728C for 1 min. The
fluorescence intensity of the double-strand-
specific SYBR Green, reflecting the amount of
formed PCR product, was monitored at the end
of each elongation step. Melting curve analysis
was performed to confirm the purity of the
PCR products. Relative expression of CCR2
was normalized by GAPDH using the DCT
method [relative expression¼ 2DCT, where
DCT¼CT(CCR2)CT(GAPDH)] [Wang et al., 2004].
Data are representative of three separate
experiments and are presented as the mean
SE from triplicates.
Western Blot Analysis
Cell lysates from LNCaP, C4-2B, DU145,
PC3, PrEC, RWPE-1, BEAS2B, A549, H1299,
MDA-MB-231,MCF-7, KAS,HBME, and hFOB
cells were prepared using standard procedures.
All the samples were measured for total protein
content using a BCA assay (Pierce, Rockford,
IL) to ensure equal loading. Loading buffer was
added to 40 mg protein and samples were boiled
prior to being resolved on 12% SDS–PAGE gels
and then transferred onto PVDF membranes
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(Bio-Rad). The blots were blocked using block-
ing reagents overnight at 48C with shaking
and then incubated for 2 h with primary anti-
body for CCR2 (diluted 1:1,000 in blocking
solution). The blots were washed and incubated
for 1 h with donkey anti-goat IgG-HRP
(1:5,000). After washing, bands were detected
using enhanced chemiluminescence (ECL)
(Amersham Biosciences, Piscataway, NJ) and
exposured to light-sensitive film. As control for
equal loading of the proteins, immunoblots for
GAPDH (Santa Cruz, CA) were performed on
the strippedmembranes. CCR2was normalized
to GAPDH, and the fold change was calculated
using themean value of fold changes from three
replicates. The data are representative of
three separate experiments and are presented
as the meanSE from triplicates.
Microarray Analysis From Meta-Analysis
of ONCOMINE Database
The expression of CCR2 transcript in PCa
tissues was obtained from meta-analysis of
cancer gene microarray meta-analysis public
database [Rhodes et al., 2004]. Statistical
analysis of differences was performed using
ONCOMINE algorithms to account for the
multiple comparisons among different studies,
similar to a meta-analysis, as previously
described [Rhodes et al., 2004].
Immunohistochemical Staining and Scoring
Tissue microarray of PCa specimens (83
Asian patients who underwent radical prosta-
tectomy with Gleason score 5 and 6: n¼ 5;
Gleason score 7: n¼ 39; Gleason score 8: n¼ 12;
Gleason score 9 and 10: n¼ 27; Pathological
stage pT2: n¼ 61; pT3 and pT4: n¼ 22) were
purchased from ISU Abxis (Seoul, Korea) with
corresponding non-neoplastic tissues (42 speci-
mens); Gift specimens (normal and benign
tissues 31 cases and carcinoma 13 cases from
AmericanmenwithGleason score 5and6: n¼ 6;
Gleason score 7: n¼ 2; Gleason score 8: n¼ 3;
Gleason score 9 and10: n¼ 2; Pathological stage
pT2: n¼ 10; pT3: n¼ 3) were kindly provided by
Cybrdi, Inc. (Frederick, MD). All slides were
stained following a modified protocol [Vakar-
Lopez et al., 2004]. Briefly, slideswere heated at
558C for 30min, deparaffinized and rehydrated,
then antigen retrieval was performed with
Target Retrieval kit from Dako (Carpinteria,
CA). Slides were incubated for 24 h at 48C with
anti-human CCR2 polyclonal antibody (1:400
dilution), or isotype control goat IgG (1:400
dilution, used as a negative control) or anti-
humanPSApolyclonal antibody (1:400 dilution,
used as a positive control). Biotinylated anti-
goat or anti-rabbit antibody (Dako) at a dilution
of 1:500 was used as the secondary antibody.
After incubation in avidin–biotin complex
solution (Dako), the staining was developed by
the diaminobenzidine method, followed by
counterstaining with hematoxylin. Quantita-
tive analysis of the CCR2 expression was
determined by scoring protein expression as
negative (score¼ 1), weak (score¼ 2), moderate
(score¼ 3), or strong (score¼ 4), which was
previously used [Sun et al., 2005]. Differences
inCCR2expressionwere evaluated statistically
using the mean scores from each case. Scoring
was performed (by both authors Dr. Jian Zhang
at the University of Pittsburgh and Dr. Yulin
Liu at the Allegheny General Hospital) without
knowledge of overall Gleason score (e.g., tumor
grade), tumor size, or clinical outcome [Perrone
et al., 2000].
Statistical Analysis
Statistical analysis was performed using
Statview software (Abacus Concepts, Berkley,
CA). ANOVA was used for initial analyses,
followed by Fisher’s protected least significant
difference for post hoc analyses. Student’s t-test
was used for analyzing the gene expression
data sets from a published cDNA microarray
database ONCOMINE [Rhodes et al., 2004].
Differences with a P< 0.05 were determined to
be statistically significant.
RESULTS
CCR2 Expression in Various Cancer Cells
To determine whether CCR2 mRNA is differ-
entially expressed by different cancer cell lines,
we first tested PCa cell lines LNCaP, C4-2B,
PC3, and DU145; lung cancer A549 and H1299;
breast cancer MCF-7 and MDA-MB-231; mye-
loma KAS cells by RT-PCR (Fig. 1A) and then
quantified by real-time RT-PCR (Fig. 1B).
HBME and hFOB cells were used as a compar-
ison for the cells from bone microenvironment;
PrEC and RWPE-1 as a control for PCa, and
BEAS2B as a control for lung cancer. All
cells expressed CCR2 mRNA, however, CCR2
mRNA expressions in PCa LNCaP, C4-2B, PC3,
and DU145 cells were significantly greater
when compared to PrEC and RWPE-1 cells
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(Fig. 1A (lanes 4–9) and Fig. 1B). Specifically,
there was about a onefold higher expression
observed in C4-2B as compared to LNCaP
(Fig. 1A (lanes 4 and 5) and Fig. 1B). CCR2
mRNA expressions in lung cancer A549 and
H1299 cells were significantly greater
compared with BEAS2B (Fig. 1A (lanes 11, 12,
and 10) and Fig. 1B). Breast cancer, MCF-7
and MDA-MB-231 cells, and myeloma KAS
cells expressed similar levels of CCR2 mRNA
compared with PCa cells (Fig. 1A (lanes 13–15)
and Fig. 1B). HBME and hFOB cells also
expressed CCR2 mRNA, but at significantly
lower levels (Fig. 1A (lanes 2 and3) andFig. 1B).
To determine whether the CCR2 protein
expression is also differentially expressed by
different cancer cells, CCR2protein levels in the
cell lysates were examined by Western blot
analysis (Fig. 1C,D). Consistent with mRNA
levels, the more aggressive cancer cells such as
C4-2B, PC3, andDU145 expressed higher levels
of CCR2 protein compared with the less aggres-
sive cancer cells LNCaP or non-neoplastic PrEC
or RWPE-1 cells. CCR2 protein expressions
in lung cancer A549 and H1299 cells were
significantly higher compared with that in
BEAS2B. MCF-7, MDA-MB-231, and KAS
expressed similar levels of CCR2 protein
compared to PCa cells, whereas HBME and
hFOB expressed low levels of CCR2.
CCR2 mRNA Expression Correlates
With PCa Progressiveness
Analysis of gene expression data sets from
cancer gene microarray meta-analysis public
database [Rhodes et al., 2004] revealed that
CCR2 mRNA expression levels increased with
PCa progressiveness (Fig. 2). Yu et al. [2004]
originally determined the gene expression
patterns in benign prostate tissues (23 cases),
localized PCa tissues (64 cases), and metastatic
PCa tissues (25 cases). CCR2mRNA expression
was significantly higher in metastatic PCa
compared to both benign prostate tissues
(P¼ 4.6 106) and localized PCa (P¼ 0.002).
Furthermore, CCR2 mRNA expression was
significantly higher in the localized PCa
compared with the benign prostate (P¼ 0.012).
To further confirm the higher expression of
CCR2 mRNA in the specimens from metastatic
PCa patients, we extracted total RNA from
benignprostate tissues, localizedPCa,PCawith
bone-metastases, PCa with liver-metastases,
and PCa with lymph node-metastases. Both
RT-PCR and real-time RT-PCR analyses
were performed on these RNAs (Fig. 3A,B).
Specimens from PCa with metastasis, specifi-
cally PCa with bone-metastases, but not
liver-metastases and lymph node-metastases,
Fig. 1. CCR2 mRNA is highly expressed by aggressive cancer
cells. CCR2 mRNA and protein expression in different cell lines
were determined by RT-PCR, real-time PCR, and Western blot
analysis.A: Total RNAwas extracted from the indicated cells and
then subjected to RT-PCR. Lane 1: DNA marker; lane 2: HBME;
lane 3: hFOB; lane 4: LNCaP; lane 5: C4-2B; lane 6: DU145; lane
7: PC3; lane 8: PrEC; lane 9: RWPE-1; lane 10: BEAS2B; lane 11:
A549; lane 12: H1299; lane 13: MDA-MB-231; lane 14: MCF-7;
and lane 15: KAS. B: Real time RT-PCR was performed and
relative CCR2 mRNA expression was calculated. *P<0.001
compared to PrEC or RWPE-1. {P<0.001 compared to LNCaP.
#P< 0.001 compared to BEAS2B. C: Cell lysates were prepared
andWestern blot analysis was performed. Lane 1: HBME; lane 2:
hFOB; lane 3: LNCaP; lane 4: C4-2B; lane 5: DU145; lane 6:
PC3; lane 7: PrEC; lane 8: RWPE-1; lane 9:BEAS2B; lane 10:
A549; lane 11: H1299; lane 12: MDA-MB-231; lane 13: MCF-7;
and lane 14: KAS.D: Quantitative data of Western blot analysis.
*P<0.001 compared to PrEC or RWPE-1. {P< 0.001 compared
to LNCaP. #P< 0.001 compared to BEAS2B.
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expressed significantly higher level of CCR2
mRNA compared to the localized PCa or benign
prostate specimens.
CCR2 Protein Expression Correlates
With Gleason Score and Pathologic Stages
To test whether the CCR2 protein is differen-
tially expressed in PCa tissues compared to
benign tissues, immunohistochemical staining
was performed on tissue microarray specimens
from 96 PCa patients and 31 normal controls.
All specimens were graded using the Gleason
score system and pathologic stage [Babaian
et al., 1995; Gleason and Mellinger, 2002].
The immunohistochemical staining revealed
that CCR2 was differentially expressed in PCa
specimens and non-neoplastic tissues (Fig. 4A),
and 81 out of 96 (84%) PCa tissue samples
expressed CCR2 at heterogeneous levels. In
contrast, 19 out of 73 (26%) non-neoplastic
tissue samples expressed CCR2, although at
lower levels. The CCR2 positive staining was
located mostly in epithelial and fibromuscular
stromal cells, but was also noted in some
extracellular areas surrounding neoplastic
glands and epithelial cells (Fig. 4A). Quantita-
tive analysis showed that levels of CCR2
expression in the malignant epithelia were
greater than in the non-neoplastic epithelia,
which correlated with Gleason score and
pathologic stage (Fig. 4B). Prostate specific
antigen (PSA), expressed by prostate epithe-
lium, was immunohistochemically stained and
used as a positive control.
DISCUSSION
Chemokines are produced by various types of
human tumors, however, only limited data have
been reported on their receptors that mediate
the cancer pathobiology. In this study, we first
reported that CCR2 mRNA and protein are
differentially expressed by various cancer cell
lines including PCa, lung cancer, breast cancer,
and myeloma. All cells expressed CCR2 mRNA
and proteins, however, their expression levels
in PCa cell lines LNCaP, C4-2B, PC3, and
DU145 were significantly higher than that of
PrEC andRWPE-1. The aggressive cancer cells,
Fig. 2. CCR2 mRNA expression correlates with PCa progres-
siveness. CCR2 mRNA levels were analyzed by using gene
expression data sets from cancer gene microarray meta-analysis
public database [Rhodes et al., 2004] thatwas originally reported
by Yu et al. [2004]. Twenty-three cases of benign prostate,
64 cases of localized PCa, and 25 cases of metastatic PCa were
included in this study. Y-axis represents normalized expression
units. Shaded boxes represent interquartile range making the
25th–75th percentile; whiskers represent 10th–90th percent
range; bars represent median. The P-value was calculated by
using the Student’s t-test.
Fig. 3. CCR2 mRNA was highly expressed in metastatic PCa
tissues. Total RNA was extracted from benign prostate tissue,
localized PCa, PCa with bone-metastases, PCa with liver-
metastases, and PCa with lymph node-metastases. RT-PCR and
real-time RT-PCR were performed. A: PCR products for CCR2
were detected in benign prostate tissues, localized PCa tissues
and PCa with metastasis tissues. GAPDH served as an internal
control. Lane 1: DNAmarker; lanes 2–4: benign prostate tissues;
lanes 5–7: Localized PCa; lanes 8–11: PCa bone-metastases;
lanes 12–13: PCa liver-metastases; lane 14: PCa lymph node-
metastases. B: Quantitative data for relative mRNA expression
(for specimen corresponding to subpart A) by real-time RT-PCR.
Data are representative of three separate experiments and is
presented as mean SE from triplicates. GAPDH served as an
internal control.
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both inPCaand lung cancer cell lines, expressed
higher levels of CCR2 compared with the less
aggressive cancer cells or benign cells.
A positive correlation between CCR2 mRNA
expression and PCa progression was further
demonstrated in this study through analyzing
an ONCOMINE Gene Array Database. Con-
sistent with the findings on the differential
CCR2 mRNA expressions in aggressive cancer
cells compared to less aggressive cancer cells,
higher mRNA expression in PCa metastatic
tissues was validated in bonemetastatic tissues
compared to the localized PCa or benign
prostate tissues by real-time RT-PCR. In
addition, the findings that tissues from PCa
with bone-metastases, but not liver-metastases
and lymph node-metastases, expressed signifi-
cantly higher level of CCR2mRNA compared to
the localized PCa or benign prostate tissues,
which suggest thatCCR2may be one of the bone
specific mediators that plays a critical role in
the crosstalk between PCa cells and the bone
microenvironment. Although we were unable
to distinguish exactly what cell type(s) might
Fig. 4. CCR2 protein expression correlateswithGleason scores
and clinical pathologic stages. Immunohistochemical staining
was performed for detection of CCR2 in human PCa and
non-neoplastic tissues. A: Representatives of staining. a: CCR2
negative staining in non-neoplastic prostate tissue.b and c: CCR2
positive staining in PCa tissues. d: PSA positive staining as
positive control. e and f: Negative staining of CCR2 isotype
control IgGantibody.Different sections of b, c, anddare from the
same patient. Original magnification: 100. c and f magnifica-
tion: 400. B: Quantitative evaluation of CCR2 expression in
PCa. Immunostaining was scored and analyzed as described in
Materials and Methods section. The mean expression scores
SD for all PCa and non-neoplastic tissues examined cases are
presented in a graphical format using error bars with 95%
confidence intervals (CI). *P<0.001 compared to non-neoplas-
tic tissues. {P< 0.01 compared to Gleason score 5 and 6
specimens. #P<0.001 compared to pathological stage T2
specimens.
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overexpress CCR2 transcripts in themetastatic
tissues, the fact that CCR2 is differentially
expressed in both PCa cell lines and tissues led
us to examine its expression in situ on PCa
specimens. Thus, we examined the CCR2
protein expressions using immunohistochem-
ical staining in specimens from PCa patients
and normal control tissues. CCR2 expressions
correlated with Gleason score as well as clinical
pathologic stages, while lower levels of CCR2
were expressed in normal prostate tissues.
CCR2 positive stainings were located mostly in
epithelial, fibromuscular stromal cells, and in
the extracellular areas surrounding neoplastic
glands and epithelial cells. These positive
stainings suggested that CCR2 was overex-
pressed not only in PrECs, but also in the bone
microenvironment. To cover broader speci-
mens, we included specimens from both Asian
and American men in this study. These results
suggested that CCR2 contributes to PCa pro-
gression.
Chemokines regulate metastatic behavior of
cancer cells through their functional receptors.
It has been reported, for example, the chemo-
kine stromal-derived factor (SDF-1; CXCL12)
and its receptor CXCR4 play important role in
various tumor cells, including PCa [Aiuti et al.,
1999; Kim and Broxmeyer, 1999] cells, homing
to bone. Tumor cells that frequently metasta-
size to bone (myeloma, breast cancer, PCa, and
neuroblastoma) all express CXCR4 [Darash-
Yahana et al., 2004; Gazitt and Akay, 2004].
However, blocking CXCR4 only partially inhi-
bits bone metastasis [Marchesi et al., 2004].
These data indicate that other factors, produced
by cancer cells or cells in the bone microenvir-
onment, may also contribute to the pathogen-
esis of cancer bone metastases. Those factors
may attract and stimulate cancer cell growth in
bone.
Recent studies have shown that the ex-
pression of CC chemokine CCL5 (RANTES) is
important in the progression of breast cancer
[Manes et al., 2003]. A chemokine receptor
antagonist of CCR5 (one of the CCL5 receptors)
inhibited experimental breast tumor growth
[Robinson et al., 2003]. Vaday et al. [2006]
recently demonstrated that PCa cells expressed
functional CCR5 receptors that may mediate
pro-malignant activities. Together with our
findings, in this study, it is shown that CCR2
is highly expressed by metastatic or aggressive
PCa cells compared to less aggressive cancer
cells, and chemokines and chemokines re-
ceptors, including MCP-1/CCR2, may have
profound effects on tumor progression.
Although there is no published data on testing
a conceivable hypothesis that CCR2 blockage
may prevent tumor growth in vivo, there is
evidence that MCP-1 deficient mice may be
protected in models of endogenous mammary
carcinoma development [Conti and Rollins,
2004], which supports and promotes re-
searchers to pursue further studies in vivo.
When PCa cells metastasize to bone, they
interact with the bone microenvironment.
These interactions result in growth of PCa cells
and osteolysis followedby osteoblastic response.
There are bidirectional interactions between
PCa cells and the bone microenvironment that
increase production and expression of unique
cytokines/chemokines and adhesion molecules
on both marrow stromal cells and PCa cells,
which drive the bone destruction process.
Among the factors, we have demonstrated in
this study that CCR2, the functional receptor
for MCP-1, may mediate PCa development
in bone. Although further studies are needed
to delineate the factors regulating CCR2 ex-
pression in PCa cells and bone cells, our data
from this study suggest that CCR2 may be a
novel therapeutic target for PCa treatment.
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